|
ES2102367T3
(es)
|
1990-05-18 |
1997-08-01 |
Hoechst Ag |
Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
|
|
DE10023486C1
(de)
|
2000-05-09 |
2002-03-14 |
Schering Ag |
Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
|
|
US20030134836A1
(en)
|
2001-01-12 |
2003-07-17 |
Amgen Inc. |
Substituted arylamine derivatives and methods of use
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
EP2385041B1
(en)
|
2003-05-01 |
2013-09-18 |
Bristol-Myers Squibb Company |
Pyrazole-amine compounds useful as kinase inhibitors
|
|
EP1627869B1
(en)
|
2003-05-20 |
2012-05-02 |
Ajinomoto Co., Inc. |
Vanilloid receptor modulators
|
|
EP1628661A2
(en)
|
2003-06-05 |
2006-03-01 |
Vertex Pharmaceuticals Incorporated |
Modulators of vr1 receptor
|
|
MXPA06003949A
(es)
|
2003-10-07 |
2006-06-27 |
Renovis Inc |
Compuestos amida como ligandos del canal de ion y su uso.
|
|
CA2563941C
(en)
|
2004-04-22 |
2014-10-07 |
Bayer Cropscience Lp |
Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions
|
|
US7906533B2
(en)
|
2004-11-03 |
2011-03-15 |
Bayer Schering Pharma Ag |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
|
EP1655297A1
(en)
|
2004-11-03 |
2006-05-10 |
Schering Aktiengesellschaft |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
|
WO2006053227A2
(en)
|
2004-11-10 |
2006-05-18 |
Synta Pharmaceuticals Corp. |
Il-12 modulatory compounds
|
|
WO2006066174A1
(en)
|
2004-12-17 |
2006-06-22 |
Eli Lilly And Company |
Thiazolopyridinone derivates as mch receptor antagonists
|
|
DE602005009021D1
(de)
|
2004-12-17 |
2008-09-25 |
Lilly Co Eli |
Neue mch-rezeptorantagonisten
|
|
EP1674467A1
(en)
|
2004-12-22 |
2006-06-28 |
4Sc Ag |
2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
|
|
WO2007058626A1
(en)
|
2005-11-16 |
2007-05-24 |
S*Bio Pte Ltd |
Indazole compounds
|
|
CN101379060B
(zh)
|
2006-02-10 |
2012-05-23 |
转化技术制药公司 |
作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
|
|
GB0606429D0
(en)
|
2006-03-30 |
2006-05-10 |
Novartis Ag |
Organic compounds
|
|
CA2644910C
(en)
|
2006-03-31 |
2014-01-28 |
Abbott Laboratories |
Indazole compounds
|
|
US20080293785A1
(en)
|
2006-04-11 |
2008-11-27 |
Connolly Peter J |
Substituted benzothiazole kinase inhibitors
|
|
CN101594909A
(zh)
|
2006-09-07 |
2009-12-02 |
比奥根艾迪克Ma公司 |
用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
|
|
EP2061786A2
(en)
|
2006-09-07 |
2009-05-27 |
Biogen Idec MA Inc. |
Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
|
|
US20080153810A1
(en)
|
2006-11-15 |
2008-06-26 |
Forest Laboratories Holdings Limited |
Indazole derivatives useful as melanin concentrating receptor ligands
|
|
KR20090094125A
(ko)
|
2006-12-08 |
2009-09-03 |
엑셀리시스, 인코포레이티드 |
Ｌｘｒ 및 ｆｘｒ 조절자
|
|
JP4785881B2
(ja)
|
2007-02-27 |
2011-10-05 |
大塚製薬株式会社 |
医薬
|
|
CA2690557A1
(en)
|
2007-06-14 |
2008-12-24 |
Schering Corporation |
Imidazopyrazines as protein kinase inhibitors
|
|
WO2009011850A2
(en)
|
2007-07-16 |
2009-01-22 |
Abbott Laboratories |
Novel therapeutic compounds
|
|
ES2457418T3
(es)
|
2007-07-16 |
2014-04-25 |
Abbvie Inc. |
Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas
|
|
CN101790519B
(zh)
|
2007-08-08 |
2013-10-16 |
默克雪兰诺有限公司 |
用于治疗多发性硬化症的结合于鞘氨醇1-磷酸(s1p)的6-氨基-嘧啶-4-羧酰胺衍生物及相关化合物
|
|
WO2009102468A1
(en)
|
2008-02-13 |
2009-08-20 |
Cgi Pharmaceuticals, Inc. |
6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
|
|
WO2010008847A2
(en)
|
2008-06-24 |
2010-01-21 |
Takeda Pharmaceutical Company Limited |
Pi3k/m tor inhibitors
|
|
CN102281919A
(zh)
|
2008-11-19 |
2011-12-14 |
先灵公司 |
二酰基甘油酰基转移酶的抑制剂
|
|
WO2010071819A1
(en)
|
2008-12-19 |
2010-06-24 |
Schering Corporation |
Bicyclic heterocyclic derivatives and methods of use thereof
|
|
WO2010072599A1
(en)
|
2008-12-23 |
2010-07-01 |
F. Hoffmann-La Roche Ag |
Dihydropyridone ureas as p2x7 modulators
|
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
|
MX2012001974A
(es)
|
2009-08-19 |
2012-04-11 |
Ambit Biosciences Corp |
Compuestos de biarilo y metodos de uso de los mismos.
|
|
WO2011046954A1
(en)
|
2009-10-13 |
2011-04-21 |
Ligand Pharmaceuticals Inc. |
Hematopoietic growth factor mimetic small molecule compounds and their uses
|
|
US8822447B2
(en)
|
2010-04-22 |
2014-09-02 |
Janssen Pharmaceutica Nv |
Indazole compounds useful as ketohexokinase inhibitors
|
|
US20130053382A1
(en)
|
2010-04-30 |
2013-02-28 |
Sunil Paliwal |
Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1)
|
|
RS56332B1
(sr)
|
2010-06-24 |
2017-12-29 |
Chemocentryx Inc |
Antagonisti c5ar
|
|
CN110003219A
(zh)
|
2010-07-13 |
2019-07-12 |
弗·哈夫曼-拉罗切有限公司 |
作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
|
|
RU2632900C2
(ru)
|
2010-11-19 |
2017-10-11 |
Лиганд Фармасьютикалс Инкорпорейтед |
Гетероциклические амины и их применение
|
|
BR112013015460B1
(pt)
|
2010-12-20 |
2022-01-25 |
Merck Serono S.A. |
Derivados de indazolil triazol, kit, e composição farmacêutica
|
|
EP2696873B1
(en)
|
2011-04-12 |
2022-08-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
|
|
WO2013042137A1
(en)
|
2011-09-19 |
2013-03-28 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocycles as irak4 inhibitors
|
|
AU2012322095B2
(en)
|
2011-10-14 |
2017-06-29 |
Ambit Biosciences Corporation |
Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases
|
|
JP6073343B2
(ja)
|
2011-10-20 |
2017-02-01 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ |
サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
|
|
GB201119401D0
(en)
|
2011-11-10 |
2011-12-21 |
Ucb Pharma Sa |
Therapeutic agents
|
|
KR101385603B1
(ko)
|
2012-05-17 |
2014-04-21 |
한국원자력의학원 |
벤조티아졸 유도체 및 암 치료를 위한 그의 용도
|
|
WO2014003483A1
(en)
|
2012-06-29 |
2014-01-03 |
Hanmi Pharm. Co., Ltd. |
Fused pyrimidine derivatives having inhibitory activity on fms kinases
|
|
WO2014011902A1
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
JP6372666B2
(ja)
|
2012-11-03 |
2018-08-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
サイトメガロウイルスの阻害剤
|
|
EP2999470B1
(en)
|
2013-05-22 |
2017-08-16 |
Children's Hospital Medical Center |
Combination therapy for mds
|
|
TWI652014B
(zh)
|
2013-09-13 |
2019-03-01 |
美商艾佛艾姆希公司 |
雜環取代之雙環唑殺蟲劑
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
EP3092226B1
(en)
|
2014-01-10 |
2019-03-13 |
Aurigene Discovery Technologies Limited |
Indazole compounds as irak4 inhibitors
|
|
LT3466955T
(lt)
|
2014-01-13 |
2021-02-25 |
Aurigene Discovery Technologies Limited |
Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
|
|
US9452986B2
(en)
|
2014-02-06 |
2016-09-27 |
Abbvie Inc. |
6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
|
|
AU2015275730A1
(en)
|
2014-06-20 |
2016-12-15 |
Aurigene Discovery Technologies Limited |
Substituted indazole compounds as IRAK4 inhibitors
|
|
JO3705B1
(ar)
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
TW201701879A
(zh)
*
|
2015-04-30 |
2017-01-16 |
拜耳製藥公司 |
Ｉｒａｋ４抑制劑組合
|
|
JP2018524372A
(ja)
|
2015-07-15 |
2018-08-30 |
アウリジーン ディスカバリー テクノロジーズ リミテッド |
Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
|
|
CN108024971A
(zh)
|
2015-07-15 |
2018-05-11 |
奥列基因发现技术有限公司 |
作为irak-4抑制剂的取代的氮杂化合物
|
|
DK3331879T3
(da)
|
2015-08-04 |
2020-08-10 |
Rigel Pharmaceuticals Inc |
Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
|
|
US20170035881A1
(en)
*
|
2015-10-19 |
2017-02-09 |
Acerta Pharma B.V. |
Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
|
|
WO2018081738A1
(en)
|
2016-10-28 |
2018-05-03 |
Children's Hospital Medical Center |
Treatment of diseases associated with activated irak
|
|
EP3600270B1
(en)
*
|
2017-03-31 |
2023-06-14 |
Aurigene Oncology Limited |
Compounds and compositions for treating hematological disorders
|
|
HUE067356T2
(hu)
*
|
2017-10-31 |
2024-10-28 |
Curis Inc |
IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220008307A
(ko)
*
|
2019-05-14 |
2022-01-20 |
르 라보레또레 쎄르비에르 |
Gly101val 돌연변이를 수반하는 bcl-2 매개 암의 치료에 사용하기 위한 bcl-2 억제제
|
|
KR20220034782A
(ko)
*
|
2019-06-12 |
2022-03-18 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
|
|
PH12022500002A1
(en)
*
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
IL300310A
(en)
|
2020-08-03 |
2023-04-01 |
Curis Inc |
Preparations and methods for treating diseases and disorders
|
|
MX2023005591A
(es)
|
2020-11-18 |
2023-05-29 |
Curis Inc |
Metodos de tratamiento de enfermedades y trastornos.
|
|
EP4319750A4
(en)
|
2021-04-08 |
2025-02-26 |
Curis, Inc. |
COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
|
|
JP2025516501A
(ja)
|
2022-05-11 |
2025-05-30 |
キュリス，インコーポレイテッド |
Ｉｒａｋ４修飾化合物による疾患及び障害の治療
|